The DS management team has both a strong background in developing drugs for the market and experience in building life science companies.


DS Biopharma have three novel assets in various stages of clinical development and intend to add more bioactive lipids to the current portfolio in the coming years.


To date, DS Biopharma have been funded privately.

Latest Press Releases

March 6, 2019

Clinical Study Shows Topical DS107 Prevents Disease Exacerbation in Atopic Dermatitis Patients

Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]
November 19, 2018

DS Biopharma announces DS107 patent grant in the US for the treatment of atopic dermatitis

Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced […]

Media coverage

November 19, 2019

Pipeline full with agents in various phases of development | Dermatology Times

The following article appeared in Dermatology Times on 19th November 2019: https://www.dermatologytimes.com/atopic-dermatitis/pipeline-full-agents-various-phases-development As dermatologists gain experience with newer atopic dermatitis medications, they’re getting glimpses of data […]

Join our mailing list

Connect with us